Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 7/20 | 0.30 |
| ▸ | APP | P05067 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299583 | 0.89 | AKR1B1 (0.37) | AKR1B1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL12299780 | 0.71 | KMT2A (0.38) | AKR1B1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL12299271 | 0.71 | AKR1B1 (0.33) | AKR1B1BACE1APP | |
| SCHEMBL12299015 | 0.70 | AKR1B1 (0.32) | AKR1B1BACE1APP | |
| SCHEMBL1825508 | 0.67 | MAPT (0.34) | AKR1B1ALDH1A1MAPK1MAPTKDM4E | |
| SCHEMBL1820451 | 0.66 | AKR1B1 (0.43) | AKR1B1MAPT | |
| SCHEMBL2378076 | 0.64 | BACE1 (0.55) | BACE1 | |
| SCHEMBL2374548 | 0.63 | BACE1 (0.40) | ALDH1A1GAAKDM4EBACE1APP | |
| SCHEMBL7948351 | 0.62 | KDM4E (0.34) | ALDH1A1MEN1MAPK1KMT2AMAPT | |
| 6-Bromo-2-(Thiophen-2-Yl)Chroman-4-One SCHEMBL1824814 | 0.60 | AR (0.58) | MAPK1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | AKR1B1 2656/4885ALDH1A1 2484/4885MEN1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.